Haloperidol is an effective antipsychotic but also one of the more side-effect-heavy ones. Extrapyramidal symptoms (EPS), sedation, and dose-related cardiac effects vary widely between patients on the same dose. CYP2D6 phenotype explains a meaningful chunk of that variation: poor metabolizers reach substantially higher plasma concentrations on standard doses and bear higher EPS risk.
Acute dystonic reactions (sudden involuntary muscle spasms, especially of the neck, jaw, or eye muscles) require immediate treatment with intramuscular benztropine or diphenhydramine. Neuroleptic malignant syndrome (high fever, muscle rigidity, autonomic instability) is rare but life-threatening and warrants emergency care.
Akathisia (restlessness), Parkinsonism (stiffness, tremor, slowed movement), and dystonia (involuntary muscle contractions) are dose-related. The higher the haloperidol concentration, the more dopamine receptors are blocked, and the more likely EPS is to emerge.
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) reduce haloperidol clearance and can essentially convert a normal metabolizer into a phenocopy of a poor metabolizer. EPS that emerges after starting a new medication is often a CYP2D6 interaction.
Tardive dyskinesia (TD) is a less reversible movement disorder that can develop after months or years of antipsychotic exposure. Higher cumulative drug exposure increases risk, which is part of why CYP2D6 status matters even before any acute side effect appears.
CYP2D6 is the principal pharmacogenetic factor for haloperidol. Other enzymes (CYP3A4, glucuronidation) play a smaller role.
CYP2D6 is one of the principal enzymes that clear haloperidol. Reduced enzyme activity slows clearance and raises plasma concentrations at any given dose. Higher concentrations mean higher D2 receptor occupancy and higher EPS risk.
Poor metabolizers reach substantially higher haloperidol concentrations and have higher rates of EPS. Intermediate metabolizers fall in between. DPWG recommends a 30 to 50 percent dose reduction for intermediate metabolizers and roughly 50 percent for poor metabolizers, or a switch to an antipsychotic with less CYP2D6 dependence. Ultrarapid metabolizers may have inadequate response at standard doses.
Most useful before starting haloperidol or after early EPS or sedation that hasn't been explained by dose alone. CYP2D6 testing is also worth considering if you've had EPS on multiple CYP2D6-metabolized antipsychotics (haloperidol, aripiprazole, brexpiprazole), which is a pattern that suggests reduced CYP2D6 activity.
Learn how genetics may affect your response to these related medications:
EPS is the broad term for movement-related side effects that emerge during antipsychotic therapy: Parkinsonism, akathisia, dystonia. Most EPS is reversible when the drug is reduced or stopped. Tardive dyskinesia is a specific form of involuntary movement disorder (typically of the face and tongue) that develops after long-term antipsychotic exposure and can persist after the drug is stopped.
Generally no. Quetiapine has lower EPS risk than haloperidol because of its different receptor binding profile and shorter D2 occupancy. Quetiapine is metabolized by CYP3A4 rather than CYP2D6, so the CYP2D6 issue doesn't carry over either.
Yes, especially for acute psychotic episodes, severe agitation, and emergency psychiatric care. The rapid onset and reliable D2 blockade are useful in those settings. For chronic outpatient management, second-generation antipsychotics with lower EPS risk are usually preferred.
Find out how your DNA may influence your response to Haloperidol and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator